Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
murine BCMA-targeted CAR-T cells
- Development stage
- Unknown
- Lead developer
- Beijing Gaobo Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Murine BCMA-targeted CAR-T cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Beijing Boren Hospital for the treatment of relapsed or refractory multiple myeloma. The therapy consists of a patient's own T cells that have been genetically engineered to express a CAR comprising a murine-derived single-chain variable fragment (scFv) specific for the B-cell maturation antigen (BCMA), typically coupled with 4-1BB costimulatory and CD3-zeta signaling domains. BCMA is a cell surface receptor highly and selectively expressed on malignant plasma cells, making it an ideal target for cellular immunotherapy. In clinical trials conducted at Beijing Boren Hospital, these murine-based CAR-T cells have been evaluated for their ability to induce deep clinical responses, and they are frequently used as a benchmark or comparator for newer humanized CAR-T constructs designed to reduce immunogenicity and improve persistence.
- Other names
- murine BCMA-targeted CAR-T cellsmurine BCMA-directed CAR-T cellsmurine anti-BCMA CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on murine BCMA-targeted CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on murine BCMA-targeted CAR-T cells.